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Abstract: Vitamin E has been proposed as a potential clinical intervention for Alzheimer’s
disease (AD) given the plausibility of its various biological functions in inﬂuencing the
neurodegenerative processes associated with the condition. The tocopherol and tocotrienol
isoforms of vitamin E have multiple properties including potent antioxidant and anti-inﬂam-
matory characteristics, in addition to inﬂuences on immune function, cellular signalling and
lowering cholesterol. Several of these roles offer a theoretical rationale for providing beneﬁt
for the treatment of AD-associated pathology. Diminished circulating concentrations of
vitamin E have been demonstrated in individuals with AD. Reduced plasma levels have
furthermore been associated with an increased risk of AD development while intake,
particularly from dietary sources, may limit or reduce the rate of disease progression. This
beneﬁt may be linked to synergistic actions between vitamin E isoforms and other micro-
nutrients. Nevertheless, randomised trials have found limited and inconsistent evidence of
vitamin E supplementation as an effective clinical intervention. Thus, despite a strong
rationale in support of a beneﬁcial role for vitamin E for the treatment of AD, the evidence
remains inconclusive. Several factors may partly explain this discrepancy and represent the
difﬁculties of translating complex laboratory evidence and dietary interactions into clinical
interventions. Methodological design limitations of existing randomised trials and restric-
tions to supplementation with a single vitamin E isoform may also limit the inﬂuence of
effect. Moreover, several factors inﬂuence individual responsiveness to vitamin E intake and
recent ﬁndings suggest variation in the underlying genetic architecture attenuates vitamin E
biological availability and activity which likely contributes to the variation in clinical
responsiveness and the failure of randomised trials to date. Importantly, the clinical safety
of vitamin E remains controversial and warrants further investigation.
Keywords: vitamin E, Alzheimer’s disease, tocopherols, tocotrienols, antioxidants
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that accounts
for up to 80% of dementia cases.1 It is clinically characterised by the insidious
onset of episodic memory impairment that evolves over time and is associated with
subsequent decline in other cognitive domains that diminish functional ability.2 Its
histopathological hallmarks include neuroﬁbrillary tangles (NFTs), amyloid plaques
and loss of neuronal synapses in the brain.3 AD represents a major global disease
burden with an estimated 50 million people currently living with dementia, a ﬁgure
expected to increase threefold by 2050 with associated global economic costs
expected to double to US$2 trillion by 2030.4,5 As such, prevention and treatment
interventions for AD are paramount, given an estimated 9.2 million deaths could be
prevented by 2050 if AD onset was delayed by one year.6
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It is widely accepted that AD pathology begins decades
before the appearance of clinical manifestations; changes
may be present up to 30 years before the onset of
symptoms.7 Advances in neuro-imaging modalities and
the ongoing development of biomarkers from cerebrosp-
inal ﬂuid (CSF) offer some aid to predicting the develop-
ment of AD in those with mild cognitive impairment
(MCI) when combined with validated clinical tests.8
However, existing therapeutic options are largely lim-
ited to delayed disease progression and ease of symptom
burden, albeit without modiﬁcation of disease-course.9
This has resulted in greater focus on the development of
alternative interventions to delay or prevent onset that
have included dietary and antioxidant measures.10
Vitamin E has been studied extensively, primarily due to
its potent antioxidant properties and the biological plausi-
bility of its potential role in combatting the pathological
processes of AD. However, its use as an effective clinical
intervention remains controversial.
This review will assess the current evidence for the
role of vitamin E as a treatment option in the context of
AD. A literature search of Medline, a major article data-
base, was conducted using the keywords “Alzheimer
Disease” AND “Vitamin E” OR “tocopherols” OR “toco-
trienols”. The keywords were searched in all possible
combinations. Original journal articles that were written
in English and published prior to 1st March 2019 were
retrieved. All studies incorporating cell, animal and human
evidence were included in addition to review articles to
achieve a comprehensive search of the topic and to
retrieve the maximum number of articles possible. A
total of 341 articles were retrieved.
Pathogenesis of AD
Several theories have proposed the onset and progression
of AD as a corollary of the uncertainty of the pathogenic
mechanisms that lead to disease and the likely overlapping
contributions they make to the phenotype observed. Since
the characteristic “plaques” and “tangles” of AD were ﬁrst
reported by Alois Alzheimer in 1907, the role of amyloid
and tau protein deposits have remained central to AD
pathogenesis.11 The amyloid cascade hypothesis postulates
that excessive accumulation of senile plaques, composed
of amyloid-beta (Aβ) protein, directly induces the clinical
manifestations of AD through neurodegeneration mediated
by inﬂammation, immunological mechanisms and the
effects of free radical species.12 Aβ is a beta-sheet protein
derived from the amyloid beta precursor protein (AβPP)
molecule through the activity of β and γ-secretase.13
Importantly, expression of the ApoE4 allele reduces elim-
ination of Aβ and is associated with increased AD risk.14
Similarly, the accumulation of intra-cellular NFTs have
been implicated in AD pathology.15 NFTs consist of
hyper-phosphorylated tau-protein, an important compo-
nent of the neuronal cytoskeleton. Signiﬁcantly, an
increased quantity of NFTs is inversely associated with
cognitive impairment and is more closely correlated with
dementia severity than Aβ plaques.16 Furthermore,
hypercholesterolaemia has been associated with AD
pathology through its association with the amyloid path-
way, although its precise role remains uncertain.17
Laboratory studies have shown higher cholesterol levels
are associated with increased proteolysis of AβPP and Aβ
production through secretase enzyme activity.18
Dysfunctional cholesterol metabolism has also been asso-
ciated with its accumulation in the brains of AD patients.19
However, the clinical application of this remains contro-
versial as evidence from randomised trials indicates that
cholesterol-reducing statins have no effect on validated
measures of cognition.20 Despite the obvious implications
of the amyloid cascade theory, several concerns have
questioned the assumption of direct causality, including
the failure of therapeutic interventions targeting the amy-
loid pathway to provide clinical beneﬁt21 and an extensive
body of evidence suggests the pathological processes of
AD are complex and multifactorial.22
The mitochondrial cascade hypothesis of AD patho-
genesis postulated that genetic variation inﬂuences the
impact of age-related mitochondrial changes which upon
reaching a threshold value initiate a pathological cascade,
including the amyloid pathway.23 In addition, critical mito-
chondrial dysfunction may precipitate other cellular and
molecular changes associated with AD including synaptic
degeneration, production of free radical species and neuro-
inﬂammation.24,25 The processes of neuro-inﬂammation
have been reported as an early event in AD, perhaps
occurring before the appearance of Aβ deposits.26 In
vitro studies have demonstrated elevation of multiple
interleukins (ILs), tumour necrosis factor-α (TNF-α) and
granulocyte macrophage colony stimulating factor (GM-
CFS) in AD murine models early in the disease process.27
Additionally, elevated levels of inﬂammatory cytokines
have been detected in the brain and CSF of AD patients.27
While it is likely each of these mechanisms contribute
to AD pathogenesis, oxidative stress (OS) represents a
common underlying theme. The role of OS in disease is
Browne et al Dovepress
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characterised by the generation of reactive oxygen species
(ROS) through the metabolism of oxygen within the mito-
chondria that manifests as structural and functional altera-
tions in various biomolecules.28 Multiple indicators of OS
are signiﬁcantly elevated in AD with detectable oxidative
effects on lipids, proteins, nucleic acids and sugars.29,30
Importantly, cerebral glucose metabolism is reduced early
in the AD process and may be accompanied by metabolic
dysregulation and increased production of ROS.31
Several factors render the brain particularly vulnerable
to the effects of ROS including its high oxygen demand
and consumption, the proportion of polyunsaturated fats in
neural tissues and the relative scarcity of endogenous
antioxidants to address this high metabolic demand.32
Interestingly, AD-associated mitochondrial defects beyond
the central nervous system represent characteristic features
of a systemic disease.33 This is supported by factors such
as diabetes mellitus, obesity and physical inactivity as
potential risk factors for AD development.34 In addition,
strong associations have been reported between vascular
risk factors and AD development, with Aβ protein deposi-
tion found within vessels early in the disease course.35 As
such, there is a strong rationale in support of systemic
antioxidant therapy as a preventative or therapeutic inter-
vention for AD with particular support for vitamin E in
accordance with its biological activities.36,37
Basis of vitamin E as a clinical
intervention in AD
Biological properties of vitamin E
Vitamin E is a collective term that describes a family of
eight naturally-occurring homologues with potent antiox-
idant properties. The group is composed of four tocopher-
ols and four tocotrienols, each of which has an α, β, γ and
δ isoform. All eight congeners are differentially distributed
within food sources such as vegetable oils, grains and
various nuts and seeds38 and α-tocopherol is the primary
isoform normally found within vitamin E supplements.39
The recommended dietary allowance for α-tocopherol is
currently 15 mg/day in adults with a recommended upper
intake level of 1000 mg/day for supplemental vitamin E as
the highest dose unlikely to result in haemorrhage - how-
ever, high-doses (>1000 mg/day) have been used in a
number of studies of vitamin E supplementation to date.32
Plasma levels of vitamin E are dependent upon the absorp-
tion, distribution and excretion rates of each isoform. All eight
homologues have lipophilic properties and are absorbed from
the intestine following ingestion in micelles formed by pan-
creatobiliary secretions.32 The plasma half-life of α-tocopherol
is estimated at 20 hrs, which is considerably longer than that of
other isoforms, particularly the tocotrienol congeners.40 This is
signiﬁcant in that α-tocopherol is therefore the predominant
isoform found in tissues whereas the other congeners are
metabolised and more quickly removed.41 Additionally,
important interactions have been previously reported between
various isoforms including antagonistic interactions between
plasma α and γ-tocopherol.42
Biological functions of vitamin E
Vitamin E has a broad range of biological functions that
vary according to the relevant isoform. The tocopherol and
tocotrienol sub-groups possess varying properties and
functions linked with the level of chemical saturation in
their molecular structures with tocopherols having phytyl
side-chains, while tocotrienols possess three carbon-car-
bon double bonds.32 However, as a collective group, the
potent antioxidant capabilities of vitamin E are well
known and each of the eight tocopherol and tocotrienol
congeners are considered free-radical scavengers.43 The
antioxidant capacity results from the presence of a hydro-
xyl group on the aromatic ring of tochocromanols that
quenches free radicals through hydrogen atom donation.44
The various vitamin E isoforms enact a key role in the
protection of cell membranes, rich in highly unsaturated
fatty acids, from oxidative damage.45 Several studies have
shown that different isoforms are differentially located
within the cell membrane and that this may inﬂuence
their biological activity in the lipid membrane.46,47 In
vivo studies have reported that the antioxidant activity of
α-tocopherol is superior to other tocopherol congeners,
followed in potency by the β, γ and δ isoforms,
respectively.48 While the effectiveness of α-tocopherol
has also been reported through in vitro evidence, it has
been suggested that its relative laboratory efﬁcacy may be
dependent upon experimental conditions.49 Tocotrienols
may exhibit more potent antioxidant activities than toco-
pherols due to their shorter side-chains enabling easier
incorporation into the cell membrane and the presence of
their unsaturated side-chain.50 However, it has been sug-
gested that α-tocopherol retains a superior in vivo role in
neuroprotection due to its relatively greater bioavailability
and preferential retention by tissues.51 Similar to tocopher-
ols, the δ-tocotrienol isoform demonstrates reduced anti-
oxidant potency compared to the other tocotrienol
congeners.48
Dovepress Browne et al
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Importantly, the scope of vitamin E activity extends
beyond its antioxidant capabilities and includes other
neuro-protective, anti-inﬂammatory and cholesterol-redu-
cing properties, in addition to inﬂuencing gene expression
and potentially ensuing AD pathology.50
Several studies have demonstrated the beneﬁcial effects of
vitamin E supplementation on various markers of inﬂamma-
tory stress, cellular signalling and immune function in humans
and its inﬂuence on AD-associated pathology.52,53
Additionally, studies in murine AD models have identiﬁed
associations between vitamin E deﬁciency and increased
expression of genes associated with AD progression including
those involved in the regulation of apoptosis, neuro-transmis-
sion and Aβ metabolism.54 Similarly, vitamin E has been
shown to confer a protective effect against hyper-phosphory-
lated tau protein.55 The enzyme-inhibiting activity of various
tocopherol and tocotrienol isoforms also incorporates several
AD-associated enzymes, including cyclo-oxygenases (COX),
which contribute to neuro-inﬂammation and OS.56 The activ-
ity of both sub-groups have also been associated with reduced
Aβ production through inhibiting secretase enzyme activity.39
Comparison of tocopherol and
tocotrienol isomers
Tocopherols are a necessary constituent of physiological
neuronal activity with high levels of the vitamin E transfer
protein (α-tocopherol transfer protein, α-TPP) found in the
cerebellum.57 Its importance is emphasised by a loss-of-
function mutation within the α-TPP gene that results in a
rare condition known as ataxia with vitamin E deﬁciency
(AVED)58 and several studies have also reported potential
beneﬁts of α-tocopherol in other neurodegenerative disor-
ders: for example, increasing duration (years) of vitamin E
supplement use has been inversely correlated with amyo-
trophic lateral sclerosis (ALS) rates while a meta-analysis
found a protective inﬂuence from moderate-high intake of
vitamin E in participants with regards to their risk of
developing Parkinson’s disease.59,60
In contrast, research on tocotrienols has been limited,
although not all are believed to be essential for normal phy-
siological function and there is no evidence to date for any
genetic mutations that alter tocotrienol metabolism and result
in clinically signiﬁcant sequelae.61 However, tocotrienols are
an important vitamin E sub-group with biological functions
that differ from tocopherols, with stronger antioxidant and
anti-inﬂammatory effects according to some measures.17
Tocotrienols inﬂuence the mevalonate pathway by
suppressing hydroxyl-methyl-glutaryl co-enzyme A (HMG-
CoA) reductase resulting in cholesterol-lowering and anti-
inﬂammatory properties that inﬂuence AD pathology.62
These ﬁndings have been reported for several tocotrienol iso-
forms including the δ congener which suppresses the action of
HMG-CoA reductase at the transcriptional level.63,64
However, combined supplementation with α-tocopherol has
been shown to attenuate these inhibitory effects with a dose-
dependent relationship in hamster models.65 This study
furthermore found that α-tocopherol supplementation alone
may act as a stimulant to HMG-CoA activity and therefore
demonstrate hypercholesterolaemic activity.65 Such interac-
tions highlight the importance of a thorough understanding
of the interactions between isoforms and the appropriate selec-
tion of congeners in interventional studies.
AD and vitamin E: human studies
Plasma, serum and CSF concentrations of
vitamin E in AD
A large number of case-control studies have previously eval-
uated vitamin E levels in the plasma, serum and CSF of
patients with AD (Table 1). An early study reported reduced
vitamin E levels in a small number of AD patients compared
with cognitively intact controls.83 Many studies have since
replicated these ﬁndings and have been summarised in a
2014 meta-analysis.84 This study reviewed the plasma status
of several micro-nutrients in AD and reported diminished
vitamin E levels in AD patients compared with cognitively
intact controls and concluded this was not as a consequence
of patient malnourishment.84 Similar ﬁndings were reported
in the sensitivity analysis of a 2017 case-control study that
found no correlation between AD severity and plasma vita-
min E levels, suggesting diminished plasma antioxidant sta-
tus may result from early disease pathology rather than as a
consequence of reduced vitamin E intake.77
The most recent meta-analysis conducted by Mullan and
colleagues (2018) evaluated 51 studies comparing the plasma
nutrient status in AD participants compared to cognitively
intact controls.85 This study reported that vitamin E was the
most extensively studied dietary plasma antioxidant and con-
cluded that vitamin E levels are 11% lower in AD patients
compared to cognitively normal subjects85 corroborating the
ﬁndings from a previous smaller meta-analysis of 17 studies.86
In addition to diminished plasma vitamin E levels in
AD, a meta-analysis of 116 studies reported signiﬁcantly
reduced levels in the central nervous system of participants
with AD and suggested nutrient status of the brain
Browne et al Dovepress
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parallels that of the systemic circulation.87 One cross-sec-
tional study was notable for its measurement of tocotrienol
isoforms: 521 subjects were recruited including 168 AD,
166 MCI cases and 187 cognitively intact controls.75 The
study reported signiﬁcantly diminished plasma vitamin E
levels for each isoform in those with AD compared to
controls and low tocopherol and tocotrienol levels were
associated with increased risk of both MCI and AD.75
Despite a substantial body of evidence in support of
reduced vitamin E levels in AD, a relatively small number
of case-control studies have reported no signiﬁcant differ-
ences in plasma levels compared with cognitively normal
controls (Table 1). Although these studies were of limited
sample size, they were supported by ﬁndings from a larger
Mendelian randomised study which included data from
two genome-wide association studies of vitamin E
(n=7,781) and AD cases and controls (17,007 AD cases
and 37,154 controls) that found no association between
circulating vitamin E levels and AD.88
Prospective studies of vitamin E
concentrations and subsequent AD risk
Several prospective cohort studies have also investigated
plasma vitamin E levels and the subsequent risk of
Table 1 Cross-sectional studies investigating vitamin E levels in AD patients
Study (Publication year) Isoform(s) Population
cases
Results
Signiﬁcant associations:
Zaman et al (1992)66 Unspeciﬁed 10 AD Lower serum vitamin E levels compared with controls.
Jimenez-Jimenez et al (1997)67 α-tocopherol 44 AD Lower vitamin E levels in both serum and CSF compared with
controls.
Sinclair et al (1998)68 α-tocopherol 25 AD Lower plasma vitamin E levels compared with controls.
Foy et al (1999)69 α-tocopherol 79 AD Lower plasma vitamin E levels compared with controls.
Bourdel-Marchasson et al
(2001)70
α-tocopherol 20 AD Lower plasma vitamin E levels compared with controls.
Polidori et al (2002)71 α-tocopherol 35 AD Lower plasma vitamin E levels and increased lipid peroxidation
compared with controls.
Mecocci et al (2002)72 α-tocopherol 40 AD Lower plasma vitamin E levels and increased oxidative damage
markers compared with controls.
Rinaldi et al (2003)73 α-tocopherol 63 AD, 25
MCI
Lower plasma vitamin E levels compared with controls.
Baldeiras et al (2008)74 α-tocopherol 42 AD, 85
MCI
Lower plasma vitamin E levels and increased oxidative damage
markers in both AD and MCI compared with controls.
Mangialasche et al (2012)75 α-, β-, γ-, δ-tocopherols &
α-, β-, γ-, δ-tocotrienols
168 AD, 166
MCI
Lower plasma vitamin E levels across all isoforms in AD and MCI
cases compared with controls.
Giavarotti et al (2013)76 α-tocopherol 23 AD Lower plasma vitamin E levels and increased oxidative stress
markers compared with controls.
Mullan et al (2017)77 α- and γ-tocopherols 251 AD Lower plasma levels of both vitamin E isoforms compared with
controls.
No signiﬁcant associations:
Schippling et al (2000)78 α-tocopherol 29 AD No signiﬁcant differences between vitamin E levels in plasma and
CSF compared with controls.
Ryglewicz et al (2002)79 α-tocopherol 26 AD Patients with vascular dementia had signiﬁcantly lower plasma
vitamin E levels than AD patients.
Charlton et al (2004)80 α-tocopherol 15 AD No signiﬁcant difference in plasma vitamin E levels compared with
controls.
Mas et al (2006)81 α-tocopherol 100 AD No signiﬁcant difference in plasma vitamin E levels compared with
controls.
von Arnim et al (2012)82 α-tocopherol 74 MCI No signiﬁcant associations between plasma vitamin E levels and
dementia.
Note: Detection method for all studies was high-performance liquid chromatography.
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment.
Dovepress Browne et al
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developing AD (Table 2). In 2010, a prospective study
assessed plasma levels of all eight vitamin E isoforms in
232 subjects aged at least 80 years from the Kungsholmen
Project with a six-year follow-up.89 Individuals with total
plasma tocopherols, tocotrienols or vitamin E in the high-
est tertile had a reduced risk of incident AD compared
with participants in the lowest tertile. The authors sug-
gested that any neuro-protective effects may result from
the combination of vitamin E isoforms rather than speciﬁ-
cally to any individual congener.89
Another prospective study evaluated vitamin E status
and magnetic resonance imaging (MRI) with regard to
MCI conversion to AD.90 Data from 253 participants
including 81 AD, 86 MCI cases and 86 cognitively intact
controls revealed lower absolute values for all vitamin E
isomers in both the AD and MCI subjects compared to
controls. The authors suggested the combination of vita-
min E measures and MRI scanning was superior to ima-
ging alone in predicting MCI conversion to AD, with 95%
sensitivity after one-year follow-up.90
Similar ﬁndings were reported from the Cardiovascular
Risk Factor, Aging and Dementia (CAIDE) study,91 which
analysed data from 140 cognitively intact participants with a
follow-up time of 8 years. Elevated values of both tocopherol
and tocotrienol isoforms were associated with a reduced risk
of “cognitive impairment”, deﬁned as the development of
either MCI or AD.91
Evaluation of vitamin E intake and AD risk
Associations between vitamin E intake through supple-
mentary or dietary sources and the risk of developing
AD have also been extensively investigated (Table 3). A
prospective study investigated vitamin E supplementation
and incident AD in a population of 633 individuals with a
mean 4.3-year follow-up and reported that none of the 27
subjects taking vitamin E supplements developed AD in
contrast to the predicted incidence of 3.9.92 Similarly, the
prospective Cache County Study reported that individuals
taking vitamin E supplements in addition to multivitamins
containing vitamin C had reduced AD risk.93 However, the
study found no signiﬁcant beneﬁt from use of vitamin E
supplements alone.93 A more recent study published in
2017 reported that vitamin E supplementation was asso-
ciated with decreased risk of cognitive decline in a cohort
of 560 AD patients from the Canadian Study of Health and
Aging although, no signiﬁcant association was detected
between vitamin E intake and AD risk speciﬁcally.94
Several prospective studies of vitamin E dietary intake
also reported beneﬁcial effects associated with reduced
AD risk. One study evaluated 815 cognitively normal
elderly individuals with a mean follow-up time of 3.9-
years and found that increased vitamin E intake from
dietary sources was associated with a lower risk of devel-
oping AD, although the beneﬁt was limited to those not
carrying the ApoE4 risk allele.95 Interestingly, this study
suggested that vitamin E supplementation from non-diet-
ary sources was not signiﬁcantly associated with dimin-
ished AD risk.95 Similar ﬁndings in a study of 5,395
participants reported that high dietary intake of both vita-
min E and vitamin C was associated with a reduced risk of
developing AD.96 This effect was greatest among smokers
and was independent of the ApoE4 risk allele.96
Furthermore, Morris and colleagues found that subjects
with higher dietary intake of vitamin E had a lower inci-
dence of AD and that plasma α- and γ-tocopherol levels
were independently associated with AD risk.97 Finally, the
Table 2 Studies investigating cross-sectional levels of vitamin E and subsequent risk of AD development
Study
(Publication
year)
Isoform(s) Study
population
Follow-
up
Results
Mangialasche
et al (2010)89
α-, β-, γ-, δ-tocopher-
ols & α-, β-, γ-, δ-
tocotrienols
232 cognitively
normal elderly
participants
6 years Higher total tocopherol, total tocotrienol and total vitamin E plasma
levels were associated with a reduced risk of AD development.
Mangialasche
et al (2013)90
α-, β-, γ-, δ-tocopher-
ols & α-, β-, γ-, δ-
81 AD, 86 MCI, 86
Control
1 year AD and MCI participants had lower plasma vitamin E levels.
Combination of plasma vitamin E and MRI was superior to MRI
alone in predicting conversion of MCI to AD.
Mangialasche
et al (2013)91
α-, β-, γ-, δ-tocopher-
ols & α-, β-, γ-, δ-
140 cognitively
normal elderly
participants
8.2 years Elevated serum tocopherols and tocotrienols were associated with
reduced risk of cognitive impairment (MCI and AD).
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; MRI, magnetic resonance imaging.
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prospective population based Rotterdam Study included
365 participants with AD and identiﬁed a modest reduc-
tion in risk over the longer term in participants from the
highest tertile of dietary vitamin E intake compared with
those in the lowest tertile, independent of any supplement
use and other potential confounders.98
However, several studies failed to detect associations
between either dietary intake or vitamin E supplementation
and AD. The Honolulu-Asia Aging Study analysed data from
3,385 men who reported taking vitamin E and vitamin C
supplements at baseline in addition to measuring AD pre-
valence ten-years later.99 Although the study identiﬁed a
protective effect of vitamin E with vascular dementia, no
association with AD risk was noted.99 The analysis of 980
individuals within the Washington Heights-Inwood
Columbia Aging Project concluded that neither supplemen-
tary nor dietary intake of vitamin E, alone or in combination,
signiﬁcantly attenuated AD risk.100 A prospective study of
2,969 individuals followed-up over a mean 5.5 years found
no association between AD risk and the use of vitamin E
supplements, with or without vitamin C.101
While these prospective studies provide limited evi-
dence for the beneﬁts of vitamin E supplementation, they
nevertheless suggest that a high intake from dietary
sources may confer some beneﬁt in reducing the risk of
developing AD compared to those with lower intake.
Randomised clinical trials of vitamin E
supplementation
Several randomised trials have investigated the efﬁcacy of
vitamin E as a potential therapeutic intervention for AD
(Table 4). The ﬁrst of these was published over 20 years
ago and was a double-blind, randomised multi-centre clin-
ical trial which compared the effectiveness of selegiline (a
selective monoamine oxidase inhibitor) and α-tocopherol
(2000 IU/day), individually or in combination, with a
placebo in 341 subjects with moderate AD for 2 years.102
Table 3 Epidemiological studies investigating associations between vitamin E intake and risk of AD
Study
(Publication
year)
Vitamin E
source
Study
population
Mean
follow-
up
Results
Signiﬁcant association:
Morris et al
(1998)92
Supplements 633 cogni-
tively-intact
elderly
4.3 years None of the vitamin E supplement users developed AD (predicted incidence of
3.9).
Zandi et al
(2004)93
Supplements 4,740 elderly 3 years Use of combined vitamin E and vitamin C supplementation was associated with
decreased AD incidence.
Basambombo
et al (2017)94
Supplements 5,269 5.2 years Use of vitamin E and/or vitamin C supplements was associated with reduced AD
risk.
Morris et al
(2002)95
Dietary 815 elderly 3.9 years High vitamin E intake from foods was associated with decreased risk of incident
AD in ApoE4 negative persons. Vitamin E supplementation was not signiﬁcantly
associated with AD risk.
Engelhart et al
(2002)96
Dietary 5,395 6 years High dietary vitamin E intake was associated with reduced risk of AD. This effect
was greatest in smokers.
Morris et al
(2005)97
Dietary 1,041 3.9 years High dietary vitamin E intake was associated with reduced AD incidence. α- and γ-
tocopherol had independently associated with delayed cognitive decline.
Devore et al
(2010)98
Dietary 5,395 9.6 years High dietary intake of vitamin E at baseline was associated with a modest reduc-
tion in AD risk over follow-up.
No signiﬁcant associations:
Masaki et al
(2000)99
Supplements 3,385 elderly
male
10 years No reduction in AD risk was detectable in those taking vitamin E supplements.
Supplement use was associated with better cognitive performance at 10-year
follow-up.
Luchsinger et
al (2003)100
Supplements
and dietary
980 elderly 4 years Neither supplemental or dietary vitamin E intake were associated with decreased
AD risk.
Gray et al
(2008)101
Supplements 2,969 elderly 5.5 years Supplemental vitamin E and/or vitamin was not associated with a reduction in AD
risk.
Abbreviations: AD, Alzheimer’s disease.
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Several outcome measures were considered including
time-to-death, institutionalisation, functional ability and
dementia severity. The study concluded that vitamin E
and selegiline slow the progression of moderate AD both
independently and as a combination therapy compared
with placebo but with no additive beneﬁt of the combined
regimen.102
A larger double-blind study was undertaken several
years later and compared the effects of 2000 IU/day of
vitamin E, donepezil or placebo daily for 3 years in 769
subjects with the amnestic subtype of MCI.103 Although
the authors did not specify the vitamin E isoform used in
supplementation, no signiﬁcant difference in the rate of
conversion to AD was found at any point during follow-up
in the group receiving vitamin E and only minimal effects
on secondary measures of cognition were detected com-
pared with those receiving placebo.103
In a small trial, 57 AD participants were randomised
(33 completed the study) to receive either vitamin E
(800 IU/day) or placebo for six-months and markers of
OS and cognitive function were assessed.104 Among
those randomised to receive vitamin E, two sub-groups
were identiﬁed: (1) those who had lower measures of OS
and retained their cognitive function and (2) those with
no signiﬁcant changes in OS levels who demonstrated
marked cognitive decline throughout the six months of
the study.104 This cognitive decline was greater in the
latter sub-group compared with the group of participants
who received placebo.
Another double-blind, randomised clinical trial (The
TEAM-AD VA Cooperative Randomised Trial) investi-
gated supplementation of α-tocopherol (2000 IU/day)
and/or memantine compared to placebo in 613 patients
with mild-to-moderate AD.105 The study reported that α-
tocopherol supplementation alone resulted in slower func-
tional decline compared with the placebo group.105
Unexpectedly, the combination of α-tocopherol and mem-
antine demonstrated less beneﬁt than α-tocopherol supple-
mentation alone, although a convincing rationale for this
was lacking. Furthermore, evaluation of the α-tocopherol
safety data suggested no signiﬁcant increase in mortality in
contrast to an earlier meta-analysis.105,107
More recently, the double-blind PREADViSE study
(2017) evaluated the effects of low-dose vitamin E
(400 IU/d, unspeciﬁed isoform) and/or selenium versus
placebo in 7,540 cognitively intact elderly men.106 The
study found that neither vitamin E nor selenium, individu-
ally or in combination, offered any beneﬁt in delaying the
onset of AD.106 Of note, Naeini and colleagues investi-
gated the effects of combined vitamin E and vitamin C
supplementation for 1 year versus placebo in elderly indi-
viduals with MCI in a double-blind, randomised trial.108
Although supplementation offered some improvement in
selected measures of oxidative stress, there were no detect-
able beneﬁts in cognition.108 A further small trial investi-
gating the effects of supplementation with vitamin E and
other nutrients similarly found reductions in measures of
OS with treatment but no derived clinical beneﬁt.109
Failure of vitamin E as a clinical
intervention so far
Since Harman ﬁrst postulated the “free radical theory of
ageing” in 1956, the potential implications for providing
“chemical means of prolonging effective life” has received
signiﬁcant attention.110 Nevertheless, evidence in support
of vitamin E providing clinical beneﬁt against AD remains
inconsistent and inconclusive. Despite substantial evidence
of increased OS in AD aetiology and reduced circulating
vitamin E levels, the ﬁndings from clinical trials investi-
gating vitamin E as an intervention have yet to match the
expectation.
This translational discrepancy is not uncommon among
studies investigating the role of OS in disease and its
implication in pathogenesis and potential therapeutic
approaches.111 Indeed, several studies have shown that
antioxidant supplementation is ineffective or possibly
even harmful.112 In the context of vitamin E and AD, the
failure of clinical trials may be due to general weaknesses
in the studies investigating OS or limitations of studies
speciﬁc to this area. A major and controversial limitation
includes determination of the most appropriate OS
markers.113,114 Consequently, it has been suggested that
disease speciﬁc proteins or combinations of markers in
large-scale panels should be considered for monitoring
therapeutic response and predicting outcomes.115 In the
speciﬁc context of AD, the use of myeloperoxidase
(MPO), trans-4-hydroxy-2-nonenal (HNE) or several
advanced glycation end products (AGEs) resulting from
glycoxidation have been suggested as potentially useful
OS markers.115
However, several factors may reﬂect the translational
difﬁculties from laboratory to clinical evidence in the
existing vitamin E studies in AD. While increased OS
and reduced plasma vitamin E levels have been associated
with AD, a weakness of many vitamin E supplementation
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trials has been their failure to measure antioxidant and
nutritional levels at baseline. As such, an unknown propor-
tion of participants may not have had sufﬁciently depleted
vitamin E levels upon study entry and therefore the like-
lihood of observing any beneﬁcial effects of vitamin E on
primary outcome measures in these individuals may have
been reduced.22 The requirement of low baseline levels for
supplementation to cause an efﬁcacious increase in plasma
levels has been highlighted in non-vitamin E studies and
suggests that supplementation is beneﬁcial only in the
setting of deﬁcient or insufﬁcient nutrient status.116
In addition, differences in study design between rando-
mised trials may explain, in part, the inconsistent ﬁndings
to date. For example, a study by Lloret and colleagues
consisted of a relatively small number of participants with
a lower vitamin E dose and shorter duration while in the
study by Sano et al there were large differences in baseline
Mini-Mental State Examinations between the placebo and
vitamin E groups.102,104 It also remains unclear whether
the duration of intervention in these studies is sufﬁcient for
the detection of clinical effects. A 2017 Cochrane review
concluded that only the study by Dysken and colleagues
(which found that that vitamin E slows functional decline
in AD) was of moderate quality and that future trials were
likely to counter its ﬁndings of a lack of support for the
beneﬁcial effects of vitamin E in AD.117
Importantly, a major limitation of trials to date may
have been the choice of intervention. While two studies
(Petersen et al and Kryscio et al) failed to specify which
vitamin E isoform was used, the remaining studies have
focused solely on α-tocopherol. There is support that sup-
plementation with a single vitamin E isoform (aside from
questions of dose and duration) is a less than optimal
approach. Firstly, there is sufﬁcient evidence for the bio-
logical activity of the other vitamin E isoforms to warrant
their investigation in randomised trials.17,61 There have
been no trials to date investigating tocotrienol supple-
ments. Secondly, the administration of high-doses of α-
tocopherol alone may inhibit the absorption of other toco-
pherol and tocotrienol isoforms, leading to a damaging
biochemical imbalance rather than clinical beneﬁt.22
Furthermore, existing epidemiological studies suggest
that dietary sources of vitamin E are more effective in
reducing the risk of developing AD than supplementation
alone. It is therefore likely that this beneﬁt can be attrib-
uted to synergistic interactions which are obscured in trials
that investigate supplementation with only a single
isoform.118 It is worth noting that dietary vitamin ETa
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consumption is more likely to reﬂect long-term intake than
supplement use which may offer partial explanation as to
why diet-based sources seem more effective than supple-
mentation in reducing associated AD risk.119
There is also evidence to suggest that the combination
of vitamin intake is inﬂuential. Vitamin C plays an impor-
tant role in the reduction of vitamin E after it has been
oxidised by free radicals and therefore in maintaining its
antioxidant capabilities in tissues.120,121 It is possible that
α-tocopherol radicals can themselves induce lipid perox-
idation in the context of inadequate co-antioxidant (includ-
ing vitamin C) levels, particularly in settings of increased
oxidative stress or where α-tocopherol levels have been
increased alone.122,123 The possibility of α-tocopherol
exhibiting pro-oxidant activity under such circumstances
is supported by a small randomised trial which found
increased plasma oxidant activity in patients receiving
vitamin E supplementation compared with placebo.124 It
may therefore be important to consider the effects of
supplementation with other vitamins in combination with
vitamin E to maximise antioxidant efﬁcacy. This is sup-
ported by studies that have shown that vitamin E contri-
butes only a relatively small proportion to overall serum
antioxidant capacity.105,125
Consideration of the complex bioavailability of vitamin
E is important as it is inﬂuenced by several factors. The
intestinal absorption of vitamin E can vary signiﬁcantly
depending on the food source and its composition of
tocopherol or tocotrienol isomers and other nutrients.126
It has been shown that various dietary compounds, includ-
ing sterols, can reduce intestinal absorption of vitamin
E.127 Furthermore, there is large variation between indivi-
duals in the availability of high-density lipoproteins
(HDLs) which are necessary for vitamin E integration
into the central nervous system.128 There is evidence to
suggest this may explain the apparently higher maximum
plasma levels of vitamin E in women compared to men.129
Several other variables, including age, smoking status
and obesity, have also been associated with variation in
vitamin E bioavailability, with reduced plasma levels
reported in those over 80 years of age although this may be
partially attributable to comorbid illness and diminished food
intake.130 Low α-tocopherol levels have also been demon-
strated in smokers, while obesity has been inversely corre-
lated with plasma α-tocopherol levels131,132 although
potential confounding through variation in dietary patterns
and nutrient intake may exist.131 Such variations may have
important consequences for determining which individuals
are likely to beneﬁt from vitamin E intervention. This con-
cept is augmented by the recent identiﬁcation of 28 genetic
polymorphisms that have been shown to inﬂuence vitamin E
absorption, metabolism and bioavailability.133,134 These
genetic variants have been proposed as a rationale that
explains the substantial individual variability of vitamin E
bioavailability and responsiveness of randomised trial
participants.133 Improved understanding of the genetic archi-
tecture that underpins vitamin E bioavailability and bioactiv-
ity will enable personalised and more effective
recommendations of vitamin E intake.135 Such factors may
also clarify responder status in vitamin E supplementation
studies and warrants further consideration.104
While vitamin E is an essential micronutrient and has
been internationally incorporated into many guidelines for
dietary intake, its safety as a clinical intervention remains
controversial.136 Signiﬁcantly, it has been reported to have
a modifying effect on platelet function and may therefore
theoretically increase the risk of clinically signiﬁcant
bleeding.137 One meta-analysis found that supplementa-
tion with low-dose vitamin E increased the risk of haemor-
rhagic stroke amongst study participants.138 These effects
may be important in the setting of individuals taking other
anticoagulant or antiplatelet agents including aspirin.
Increased risk of prostate cancer has also been linked
with vitamin E supplementation.139 Similar concerns
have been raised by several meta-analyses which con-
cluded that vitamin E supplementation may lead to
increased overall mortality.107,112 However, the conclu-
sions of such meta-analyses have been questioned and
different analytical approaches have produced contradic-
tory results.140,141 Therefore, the potential adverse effects
of vitamin E remain an important clinical consideration
and should be explored in future studies.
Several reviews that provide an overview to various
aspects of the relationship between vitamin E and AD
already exist.39,61 However, this narrative review is
broader in scope with a ﬂexible structure which has
allowed the authors to be more exploratory and current
in their approach that considers the use of vitamin E as a
potential therapeutic for the treatment of AD. This review
reﬂects certain points based on the authors’ experience and
uses a speciﬁed strategy that details how the literature was
searched (keywords), time limits of searches, and biblio-
graphic databases accessed. The methodological approach
described provides a reference point in time from which
future narrative reviews may focus on new literature,
thereby limiting redundancy.
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Conclusions
In spite of a strong rationale for the role of vitamin E as an
effective intervention for AD, the existing clinical evi-
dence remains inconclusive. This review has presented
ﬁndings from cross-sectional studies that reported signiﬁ-
cantly lower plasma and CSF levels of vitamin E in those
with AD. Additionally, reduced plasma vitamin E status
has been associated with increased future risk of develop-
ing AD. Epidemiological studies have offered mixed
results with regards to vitamin E supplementation but
have suggested that intake of high levels of vitamin E
from dietary sources may be beneﬁcial. However, clinical
trials to date have investigated only the α-tocopherol iso-
form and have several limitations including failure to
measure antioxidant and nutritional levels of participants
at baseline. Therefore, there is insufﬁcient evidence to
accept or reject the premise that vitamin E is an effective
clinical intervention for delaying or preventing the onset of
AD and further research is necessary. Importantly, inves-
tigation of the underlying genetic architecture with regard
to responder status to vitamin E supplementation is war-
ranted, given it is a likely signiﬁcant contributor to the
failure of clinical trials to date.
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